Best Healthcare Stocks for 2026
Pharma, biotech, managed care, and devices, screened with Health and Quality pillars weighted above headline growth to filter out cash-burning outliers.
Healthcare ranges from pharma and biotech to managed care and devices. Pre-revenue biotechs distort sector averages on growth and quality factors, so the composite score weights Health (balance-sheet runway) and Quality (margin durability) higher than headline growth. The "growing fast while burning cash" pattern gets filtered down by the Health pillar.
Data as of (updated daily)
Top 20 Healthcare stocks by composite score
| # | Ticker | Name | Composite |
|---|---|---|---|
| 1 | INCY.US | Incyte Corporation | 83.4 |
| 2 | 002001.SHE | Zhejiang Nhu Co Ltd | 78.7 |
| 3 | 688578.SHG | Shanghai Allist Pharmaceuticals Co. Ltd. A | 76.9 |
| 4 | MERK.JK | Merck Tbk | 76.9 |
| 5 | 300573.SHE | Shenyang Xingqi Pharmaceutical Co Ltd | 76.7 |
| 6 | N1BI34.SA | Neurocrine Biosciences Inc. | 75.9 |
| 7 | NBIX.US | Neurocrine Biosciences Inc | 75.8 |
| 8 | 0950.HK | Lee’s Pharmaceutical Holdings Ltd | 75.2 |
| 9 | A1SN34.SA | Ascendis Pharma A/S | 74.9 |
| 10 | 002901.SHE | Double Medical Technology Inc | 74.8 |
| 11 | 300677.SHE | Shandong Intco Medical Products Co Ltd | 73.6 |
| 12 | ZVRA.US | Zevra Therapeutics Inc. | 73.5 |
| 13 | 002365.SHE | Qianjiang Yongan Pharmaceutical Co Ltd | 73.3 |
| 14 | 300206.SHE | Edan Instruments Inc | 73.3 |
| 15 | 096760.KO | Jw Holdings | 73.1 |
| 16 | BIZ.BK | Business Alignment Public Company Limited | 72.7 |
| 17 | 301033.SHE | Medprin Regenerative Medical Technologies Co. Ltd. | 72.5 |
| 18 | 002653.SHE | Xizang Haisco Pharmaceutical Group Co Ltd | 72.5 |
| 19 | 688336.SHG | Sunshine Guojian Pharmaceutical Shanghai Co Ltd | 72.5 |
| 20 | 000423.SHE | Shan Dong Dong-E E-Jiao Co Ltd | 72.2 |
Want to drill into Healthcare stocks?
The full screener applies the Healthcare sector filter and lets you stack 30+ more filters on top: market cap, country, dividend yield, and the four pillar scores.
Open in screener →Explore related pages
Healthcare by strategy
Healthcare by country
Industries in Healthcare
Recent Healthcare insights
- Analysis
TSHA Analysis: 78.6% Revenue Growth Offsets -37.3% ROE for $1.51B Biotech
$TSHA revenue surged 78.6%, yet a -37.3% ROE reflects high capital costs during clinical expansion.
- Analysis
DaVita Analysis: 57.9% ROE and 12.4x P/E Signal Defensive Value Opportunity
$DVA generates an elite 57.9% ROE, placing it in the top 20% of global stocks for capital efficiency.
- Analysis
Incyte (INCY) Analysis: 30.4% ROE and 15.28 P/E Signal Undervalued Growth
$INCY holds an 81/100 Total Score, placing it in the top tier of nearly 50,000 tracked equities.
- Analysis
GSK Analysis: 28.3% ROE and 13.01 P/E Signal Deep Value Opportunity
$GSK delivers an elite 28.3% ROE, generating nearly 30 cents of profit per dollar of shareholder equity.
- Hidden Gems
CAAS Trades at 4.5x Earnings vs. 35.8x Peer Average
CAAS trades at an ultra-compressed P/E of 4.45 with a 75/100 valuation score, significantly below the peer average of 35.8x, suggesting substantial undervaluation.
Methodology: How we score stocks. Data refreshed nightly around 03:30 ET. This page lists the top 20 by composite score; use the screener for the full ranked list.